Abstract
With the recognition of the key role of volume loss in the facial aging process, injectable dermal fillers and volumizers have become increasingly important treatment options for recontouring and rejuvenating the aging face. While replacement fillers effectively correct individual lines and wrinkles, volumizing agents that replace collagen provide a longer-lasting, volume-based alternative. Poly-l-lactic acid (PLLA) has been shown to increase dermal thickness and volume for up to 2 years and beyond. Although early clinical use of this agent in patients with HIV-associated facial lipoatrophy was associated with a significant rate of nodule or papule formation, subsequent experience has helped define the proper reconstitution volumes and injection techniques for optimizing results and minimizing nodule/papule formation. While injectable PLLA has been used successfully for rejuvenation of most facial areas, increasing experience suggests that it is a versatile agent capable of providing aesthetic enhancement in multiple areas of the body, including the dorsum of the hands, the décolleté, the neck, the buttocks, the medial ankles, and acne scars. Although the current published experience in these areas is limited, further studies and clinical use of injectable PLLA will clarify the potential of this agent as a minimally invasive alternative and/or adjunct to surgery for restoring volume loss in multiple anatomic areas.
Level of Evidence V
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.
Similar content being viewed by others
References
American Society for Aesthetic Plastic Surgery (2010) Cosmetic surgery national data bank statistics. http://www.surgery.org/sites/default/files/2009stats.pdf. Accessed 1 June 2010
Beer K (2007) A single-center, open-label study on the use of injectable poly-l-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg 33(Suppl 2):S159–S167
Beer K (2009) Dermal fillers and combinations of fillers for facial rejuvenation. Dermatol Clin 27:427–432
Burgess CM, Quiroga RM (2005) Assessment of the safety and efficacy of poly-l-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 52:233–239
Butterwick K, Lowe NJ (2009) Injectable poly-l-lactic acid for cosmetic enhancement: learning from the European experience. J Am Acad Dermatol 61:281–293
Butterwick KJ (2005) Rejuvenation of the aging hand. Dermatol Clin 23:515–527
Donath AS, Glasgold RA, Glasgold MJ (2007) Volume loss versus gravity: new concepts in facial aging. Curr Opin Otolaryngol Head Neck Surg 15:238–243
Fitzgerald R, Graivier MH, Kane M, Lorenc ZP, Vleggaar D, Werschler WP, Kenkel JM (2010) Appropriate selection and application of nonsurgical facial rejuvenation agents and procedures: panel consensus recommendations. Aesthet Surg J 30(Suppl):36S–45S
Fitzgerald R, Vleggaar D (2009) Using poly-l-lactic acid (PLLA) to mimic volume in multiple tissue layers. J Drugs Dermatol 8(10 Suppl):s5–s14
Gogolewski S, Jovanovic M, Perren SM, Dillon JG, Hughes MK (1993) Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 27:1135–1148
Goldberg DJ (2009) Breakthroughs in US dermal fillers for facial soft-tissue augmentation. J Cosmet Laser Ther 11:240–247
Goldman MP (2011) Cosmetic use of poly-l-lactic acid: my technique for success and minimizing complications. Dermatol Surg 37:688–693
Hanke CW, Redbord KP (2007) Safety and efficacy of poly-l-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 6:123–128
Hirmand H (2010) Anatomy and nonsurgical correction of the tear trough deformity. Plast Reconstr Surg 125:699–708
Kates LC, Fitzgerald R (2008) Poly-l-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review. Aesthet Surg J 28:397–403
Kulkarni RK, Pani KC, Neuman C, Leonard F (1966) Polylactic acid for surgical implants. Arch Surg 93:839–843
Lacombe V (2009) Sculptra: a stimulatory filler. Facial Plast Surg 25:95–99
Lam SM, Azizzadeh B, Graivier M (2006) Injectable poly-l-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 118:55S–63S
Lemperle G, Gauthier-Hazan N (2009) Foreign body granulomas after all injectable dermal fillers: part 2. Treatment options. Plast Reconstr Surg 123:1864–1873
Lemperle G, Morhenn V, Charrier U (2003) Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg 27:354–366
Lorenc ZP (inventor) (1997) Resorbable surgical appliance for use in supporting soft tissue in a superior position. US Patent 5,611,814
Lowe NJ, Maxwell CA, Lowe P, Shah A, Patnaik R (2009) Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg 35(Suppl 1):344–349
Lupo MP (2008) Natural look in volume restoration. J Drugs Dermatol 7:833–839
Matsudo PK, Toledo LS (1988) Experience of injected fat grafting. Aesthetic Plast Surg 12:35–38
Mazzuco R, Hexsel D (2009) Poly-l-lactic acid for neck and chest rejuvenation. Dermatol Surg 35:1228–1237
Mest DR, Humble GM (2009) Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-l-lactic acid. Aesthetic Plast Surg 33:654–656
Mest DR, Humble GM (2009) Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study. Dermatol Surg 35(Suppl 1):350–359
Moyle GJ, Brown S, Lysakova L, Barton SE (2006) Long-term safety and efficacy of poly-l-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 7:181–185
Narins RS (2008) Minimizing adverse events associated with poly-l-lactic acid injection. Dermatol Surg 34(Suppl 1):S100–S104
Narins RS, Baumann L, Brandt FS, Fagien S, Glazer S, Lowe NJ, Monheit GD, Rendon MI, Rohrich RJ, Werschler WP (2010) A randomized study of the efficacy and safety of injectable poly-l-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles. J Am Acad Dermatol 62:448–462
Pistner H, Gutwald R, Ordung R, Reuther J, Muhling J (1993) Poly(l-lactide): a long-term degradation study in vivo I. Biological results. Biomaterials 14:671–677
Ralston JP, Blume JE, Zeitouni NC (2006) Treatment of postoperative soft tissue loss with injectable poly-l-lactic acid. J Drugs Dermatol 5:1000–1001
Redaelli A (2006) Cosmetic use of polylactic acid for hand rejuvenation: report on 27 patients. J Cosmet Dermatol 5:233–238
Sadick NS, Anderson D, Werschler WP (2008) Addressing volume loss in hand rejuvenation: a report of clinical experience. J Cosmet Laser Ther 10:237–241
Salles AG, Lotierzo PH, Gimenez R, Camargo CP, Ferreira MC (2008) Evaluation of the poly-l-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 32:753–756
Sculptra® [package insert] (2009) Dermik Laboratories, a business of sanofi-aventis U.S. LLC, Bridgewater
Sculptra® Aesthetic [package insert] (2009) Dermik Laboratories, a business of sanofi-aventis U.S. LLC, Bridgewater, NJ
Shaw RB Jr, Katzel EB, Koltz PF, Kahn DM, Girotto JA, Langstein HN (2010) Aging of the mandible and its aesthetic implications. Plast Reconstr Surg 125:332–342
Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, Bousquet R, Katz P, Costagliola D, Katlama C (2003) Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17:2471–2477
Vleggaar D (2005) Facial volumetric correction with injectable poly-l-lactic acid. Dermatol Surg 31(11 Pt 2):1511–1518
Vleggaar D (2006) Soft-tissue augmentation and the role of poly-l-lactic acid. Plast Reconstr Surg 118(3 Suppl):46S–54S
Vleggaar D, Fitzgerald R (2008) Dermatological implications of skeletal aging: a focus on supraperiosteal volumization for perioral rejuvenation. J Drugs Dermatol 7:209–220
Werschler WP (2007) Advanced injection techniques of poly-l-lactic acid: a case-based presentation. Dermatol Ther 20(Suppl 1):S16–S19
Werschler WP, Weinkle S (2005) Longevity of effects of injectable products for soft-tissue augmentation. J Drugs Dermatol 4:20–27
Woerle B, Hanke CW, Sattler G (2004) Poly-l-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 3:385–389
Acknowledgments
Editorial support for this article was provided by Elizabeth Daro-Kaftan, PhD, of Peloton Advantage, LLC, and funded by sanofi-aventis U.S. LLC, a sanofi company.
Conflict of interest
The author has no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lorenc, Z.P. Techniques for the Optimization of Facial and Nonfacial Volumization with Injectable Poly-l-lactic Acid. Aesth Plast Surg 36, 1222–1229 (2012). https://doi.org/10.1007/s00266-012-9920-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00266-012-9920-3